WO2002072794A3 - Immunoglobulin superfamily proteins - Google Patents

Immunoglobulin superfamily proteins Download PDF

Info

Publication number
WO2002072794A3
WO2002072794A3 PCT/US2002/009052 US0209052W WO02072794A3 WO 2002072794 A3 WO2002072794 A3 WO 2002072794A3 US 0209052 W US0209052 W US 0209052W WO 02072794 A3 WO02072794 A3 WO 02072794A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin superfamily
igsfp
superfamily proteins
provides
proteins
Prior art date
Application number
PCT/US2002/009052
Other languages
French (fr)
Other versions
WO2002072794A2 (en
Inventor
Henry Yue
Yuming Xu
Kavitha Thangavelu
Bridget A Warren
Y Tom Tang
Brendan M Duggan
Uyen K Tran
Mariah R Baughn
Cynthia D Honchell
Neil Burford
Ian J Forsythe
Junming Yang
Patricia M Mason
Original Assignee
Incyte Genomics Inc
Henry Yue
Yuming Xu
Kavitha Thangavelu
Bridget A Warren
Y Tom Tang
Brendan M Duggan
Uyen K Tran
Mariah R Baughn
Cynthia D Honchell
Neil Burford
Ian J Forsythe
Junming Yang
Patricia M Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Henry Yue, Yuming Xu, Kavitha Thangavelu, Bridget A Warren, Y Tom Tang, Brendan M Duggan, Uyen K Tran, Mariah R Baughn, Cynthia D Honchell, Neil Burford, Ian J Forsythe, Junming Yang, Patricia M Mason filed Critical Incyte Genomics Inc
Priority to US10/471,449 priority Critical patent/US20040097711A1/en
Priority to EP02726671A priority patent/EP1409655A4/en
Priority to JP2002571850A priority patent/JP2004533222A/en
Priority to AU2002257088A priority patent/AU2002257088A1/en
Priority to CA002440618A priority patent/CA2440618A1/en
Publication of WO2002072794A2 publication Critical patent/WO2002072794A2/en
Publication of WO2002072794A3 publication Critical patent/WO2002072794A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)

Abstract

The invention provides human immunoglobulin superfamily proteins (IGSFP) and polynucleotides which identify and encode IGSFP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of IGSFP.
PCT/US2002/009052 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins WO2002072794A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/471,449 US20040097711A1 (en) 2002-03-12 2002-03-12 Immunoglobulin superfamily proteins
EP02726671A EP1409655A4 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins
JP2002571850A JP2004533222A (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins
AU2002257088A AU2002257088A1 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins
CA002440618A CA2440618A1 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US27524901P 2001-03-12 2001-03-12
US60/275,249 2001-03-12
US31681001P 2001-08-31 2001-08-31
US60/316,810 2001-08-31
US32397701P 2001-09-21 2001-09-21
US60/323,977 2001-09-21
US34844701P 2001-10-26 2001-10-26
US60/348,447 2001-10-26
US34388001P 2001-11-02 2001-11-02
US60/343,880 2001-11-02

Publications (2)

Publication Number Publication Date
WO2002072794A2 WO2002072794A2 (en) 2002-09-19
WO2002072794A3 true WO2002072794A3 (en) 2004-01-29

Family

ID=27540591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009052 WO2002072794A2 (en) 2001-03-12 2002-03-12 Immunoglobulin superfamily proteins

Country Status (5)

Country Link
EP (1) EP1409655A4 (en)
JP (1) JP2004533222A (en)
AU (1) AU2002257088A1 (en)
CA (1) CA2440618A1 (en)
WO (1) WO2002072794A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
MXPA04001986A (en) * 2001-08-29 2004-06-07 Genentech Inc Compositions and methods for the treatment of immune related diseases.
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
WO2004000221A2 (en) * 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
US20040248257A1 (en) * 2003-04-30 2004-12-09 The Scripps Research Institute SPEX compositions and methods of use
CA2586615C (en) * 2004-11-12 2017-06-27 Genentech, Inc. Pro87299 (btla), and variants thereof, for treating immune related disorders
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
JP2016533318A (en) * 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Agents targeting RGMA / neogenin cis interaction or lipid rafts and use of the agents in therapeutic methods
EP2905622A1 (en) * 2014-02-07 2015-08-12 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnosis of a neurological disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530080A (en) * 1998-11-19 2002-09-17 インサイト・ファーマスーティカルズ・インコーポレイテッド Immunoglobulin / Superfamily / Protein
JP2002538841A (en) * 1999-03-18 2002-11-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 27 human secretory proteins
EP1250426A2 (en) * 1999-12-01 2002-10-23 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding same
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001270215A1 (en) * 2000-06-27 2002-01-08 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
EP1354042A2 (en) * 2000-12-29 2003-10-22 Curagen Corporation Proteins and nucleic acids encoding same
WO2002099060A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Dgks as modifiers of the p53 pathway and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] June 2001 (2001-06-01), NAGASE ET AL., XP002970308, accession no. NCBI Database accession no. (BAB47496) *
See also references of EP1409655A4 *

Also Published As

Publication number Publication date
EP1409655A2 (en) 2004-04-21
JP2004533222A (en) 2004-11-04
WO2002072794A2 (en) 2002-09-19
CA2440618A1 (en) 2002-09-19
AU2002257088A1 (en) 2002-09-24
EP1409655A4 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
WO2000029583A3 (en) Immunoglobulin superfamily proteins
WO2003027228A3 (en) Receptors and membrane-associated proteins
WO2002038602A3 (en) Secreted proteins
WO2003048305A3 (en) Receptors and membrane-associated proteins
WO2002072794A3 (en) Immunoglobulin superfamily proteins
WO2002048337A3 (en) Secreted human proteins
WO2001098353A3 (en) Secreted proteins
WO2003029437A3 (en) Secreted proteins
WO2001079291A3 (en) Secreted proteins
WO2003004615A3 (en) Secreted proteins
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2002094990A3 (en) Receptors and membrane-associated proteins
WO2002070669A3 (en) Secreted proteins
WO2002086069A3 (en) Secreted proteins
WO2003068943A3 (en) Secreted proteins
WO2003054219A3 (en) Nucleic acid-associated proteins
WO2002053719A3 (en) Cytoskeleton-associated proteins
WO2002026982A3 (en) Secreted human proteins
WO2003025130A3 (en) Receptors and membrane-associated proteins
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2002057454A3 (en) Receptors and membrane-associated proteins
WO2003038052A3 (en) Nucleic acid-associated proteins
WO2003087300A3 (en) Secreted proteins
WO2002040671A3 (en) Immunoglobulin superfamily proteins
WO2002079441A3 (en) Secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002571850

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10471449

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2440618

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002726671

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002726671

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002726671

Country of ref document: EP